Sibutramine is a norepinephrine, serotonin and dopamine reuptake inhibitor indicated to assist with weight loss in obesity. Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.
- Mechanism
- Curator reviewed
Sibutramine produces its therapeutic effects by inhibition of norepinephrine (NE), serotonin (5-hydroxytryptamine, 5-HT), and to a lesser extent, dopamine reuptake at the neuronal synapse. By inhibiting the reuptake of these neurotransmitters, sibutramine promotes a sense of satiety and decrease in appetite, thereby reducing food intake. Data from animal studies also suggest that sibutramine may also increase energy expenditure through thermogenic effects in both the basal and fed states, but this has not been confirmed in humans. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines.
- Primary indication
- For the treatment of obesity.Curator reviewed · 1 structured indication
- Formula / weight
- C17H26ClN · 279.848 g/mol (avg)
- First approval
- Canada, 2001 · United States, 2010
- Code names
- HSDB 7209
Resolves to
UNAANXDKBXWMLN-UHFFFAOYSA-NSMILESCC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Sibutramine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account